We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel
News

Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel

Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel
News

Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nanosphere, Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Verigene® F5 / F2 / MTHFR Nucleic Acid Test, which detects disease-associated gene mutations that can contribute to blood coagulation disorders and difficulties metabolizing folate (vitamin B-12).

This marks the second nanotechnology-based assay cleared by the FDA to run on the Verigene® System, following clearance in September of the company’s Verigene® Warfarin Metabolism Nucleic Acid Test.

The Verigene® F5 / F2 / MTHFR Nucleic Acid Test is the first FDA-cleared test for the identification of mutations in three specific genes that together can increase an individual’s risk for dangerous blood clots and their leading complication, stroke.

According to the National Hemophilia Foundation, more than 600,000 Americans die from abnormal blood clots each year. Patients that test positively for an increased risk of blood clots can be managed with anti-coagulant therapy such as warfarin. Hyper-coagulation tests for mutations associated with a predisposition to blood clots are currently among the most frequently conducted human genetic tests.

The test is available in single and multi target (multiplex) formats, allowing users to select the test cartridge that best fits the clinical indications for testing.

Advertisement